Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688608 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
A Phase 2 study of Anaplastic Thyroid Cancer, sponsored by Saad A Khan.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02688608: Completed Phase 2 study of Anaplastic Thyroid Cancer, sponsored by Saad A Khan.
NCT02688608 is a Phase 2 study of Anaplastic Thyroid Cancer that has completed, run by Saad A Khan. The registered enrollment target is 6 participants, below the 28-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688608, a Phase 2 study of Anaplastic Thyroid Cancer, has completed, sponsored by Saad A Khan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done because there are currently no approved and no commonly working targeted therapies in anaplastic thyroid cancer (ATC). This is an area of urgent need for patients, not just for approved treatments but also rationally-designed clinical trials designed specifically for ATC. Patients diagnosed with anaplastic thyroid cancer have a very high likelihood of dying because of their disease. As such there is a clear need for improving therapy for ATC.
Primary Outcome
Overall response (OR) represents those participants that collectively achieve either complete response (CR) or partial response (PR) within 18 months, as defined below per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Complete Response (CR) = Disappearance of all target lesions * Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR * Progressive disease (PD) = 20% increase in the sum of the longest diam
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-10 |
| Phase | Phase 2 |
What the finished NCT02688608 record still lists
NCT02688608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 28-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Anaplastic Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02688608 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02688608 about?
NCT02688608 is a clinical study titled "Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer". This study is being done because there are currently no approved and no commonly working targeted therapies in anaplastic thyroid cancer (ATC). This is an area of urgent need for patients, not just for approved treatments but also rationally-designed clinical trials designed specifically for ATC. Pa...
What is the current status of trial NCT02688608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2016-10. Estimated completion is 2021-10.
What conditions does trial NCT02688608 study?
This clinical trial studies the following conditions: Anaplastic Thyroid Cancer.
What interventions are being tested in trial NCT02688608?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02688608?
This trial is sponsored by Saad A Khan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02688608 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
-
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia